Elzeiny, N., Hammouda, A., Nabih, E., Mohamed, S. (2018). The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients. The Egyptian Journal of Hospital Medicine, 72(10), 5367-5370. doi: 10.21608/ejhm.2018.11278
Noha Mohamed Hany M. Elzeiny; Abd-El-Rahman M. A. Hammouda; Enas Samir Nabih; Sherif Monier Mohamed. "The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients". The Egyptian Journal of Hospital Medicine, 72, 10, 2018, 5367-5370. doi: 10.21608/ejhm.2018.11278
Elzeiny, N., Hammouda, A., Nabih, E., Mohamed, S. (2018). 'The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients', The Egyptian Journal of Hospital Medicine, 72(10), pp. 5367-5370. doi: 10.21608/ejhm.2018.11278
Elzeiny, N., Hammouda, A., Nabih, E., Mohamed, S. The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients. The Egyptian Journal of Hospital Medicine, 2018; 72(10): 5367-5370. doi: 10.21608/ejhm.2018.11278
The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients
1Medical Biochemistry and Molecular Biology departement, Faculty of Medicine, Ain Shams University
2Internal Medicine and Gastroenterology Department, Faculty of Medicine, Ain Shams University
Abstract
Background: there is an increasing interest in using microRNAs (miRNAs) as biomarkers in liver disease. Diagnostic biomarkers in hepatitis C serve as a great benefit for the early treatment of HCV. Aim of the Work: the aim of this study was to evaluate the expression of miRNA-16 in Egyptian patients infected with HCV and their relation to different biochemical and clinicopathological parameters. Patients and Methods: twenty-five subjects were chosen, 16 HCV infected and 9 healthy controls. Collection, processing and storage of serum for evaluation of miRNA16 using RT-qPCR was done. We evaluated the power of miRNA as a diagnostic tool using ROC curve analysis. The prognostic significance of the investigated parameters in HCV patients was explored. Results: there is a highly significant difference of miRNA 16 expression between HCV patients and healthy controls. miRNA 16 has great sensitivity and specificity for differentiating between patients with HCV and healthy controls. Conclusion: miRNA 16 can be used as a potential diagnostic biomarker for HCV. In addition, it could be used for staging of the disease.
View on SCiNiTO
Top